Most Read Articles
Roshini Claire Anthony, 09 Oct 2020

The risk of falls and subsequent injuries (eg, fractures) may be elevated in individuals with diabetes compared with the general population, according to a nationwide cohort study from Denmark.

Audrey Abella, 10 Sep 2020
Interim results of REGENERATE* trial highlight the ability of experimental noninvasive tests to evaluate treatment response in adults with NASH** and advanced liver fibrosis who are receiving obeticholic acid (OCA).
Rachel Soon, 28 Aug 2020
MOH Director-General Tan Sri Dato' Seri Dr Noor Hisham Abdullah speaks about NHMS 2019 and pharmacists' roles in combating NCDs among Malaysians.
Jairia Dela Cruz, 23 Sep 2020
The combination of pitavastatin and fenofibrate appears to have superior effect on non-high-density lipoprotein cholesterol (non–HDL-C), as well as other lipids, compared with a statin alone in high-risk patients with mixed dyslipidemia, according to a study.

Cycline antibiotics may increase risk of pseudotumour cerebri syndrome

28 Jul 2019

Use of cycline antibiotics (CAs) is associated with an elevated risk of pseudotumour cerebri syndrome (PTCS) or papilledema, suggests a recent study. However, no statistically significant link between CA use and PTCS development is seen when accounting for confounding factors.

“Moreover, there was no dose-response effect whereby greater CA use was associated with a higher PTCS risk,” the authors said.

Of the 728,811 patients (mean age, 34.7 years; 72 percent female) included, 42.0 percent filled ≥1 CA prescription. Among the CA users, 170 (0.06 percent) were diagnosed with papilledema or PTCS as compared with 121 (0.03 percent) among the 57.0 percent of patients who were nonusers (p<0.0001).

The unadjusted model revealed that every additional year of CA use correlated with a 70-percent (doxycycline: hazard ratio [HR], 1.70, 95 percent CI, 0.98–2.97; p=0.06) or a 91-percent (minocycline: HR, 1.91, 1.11–3.29; p=0.02) increased risk of papilledema or PTCS as compared with nonusers.

The increased risk of PTCS or papilledema with CA use was no longer statistically significant (doxycycline: p=0.06; minocycline: p=0.08) after adjusting for confounders.

The study included patients (aged 12–65 years) with a diagnosis of acne, blepharitis or dry eye syndrome who were enrolled in a nationwide managed care network between 1 January 2001 and 31 December 2015, and who had no pre-existing diagnosis of papilledema or PTCS. The risk of developing papilledema or PTCS from exposure to CAs was assessed using multivariable Cox regression modeling.

The study was limited by its reliance on claims data, which lack clinical data.

“CAs are commonly used to treat acne, blepharitis and dry eye syndrome,” the authors said. “Prescribers or patients may hesitate to use CAs because they may increase the risk of PTCS.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 09 Oct 2020

The risk of falls and subsequent injuries (eg, fractures) may be elevated in individuals with diabetes compared with the general population, according to a nationwide cohort study from Denmark.

Audrey Abella, 10 Sep 2020
Interim results of REGENERATE* trial highlight the ability of experimental noninvasive tests to evaluate treatment response in adults with NASH** and advanced liver fibrosis who are receiving obeticholic acid (OCA).
Rachel Soon, 28 Aug 2020
MOH Director-General Tan Sri Dato' Seri Dr Noor Hisham Abdullah speaks about NHMS 2019 and pharmacists' roles in combating NCDs among Malaysians.
Jairia Dela Cruz, 23 Sep 2020
The combination of pitavastatin and fenofibrate appears to have superior effect on non-high-density lipoprotein cholesterol (non–HDL-C), as well as other lipids, compared with a statin alone in high-risk patients with mixed dyslipidemia, according to a study.